These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20723288)

  • 1. [Analysis of CEBPA mutation in acute myeloid leukemia].
    Zhang Y; Zhang SJ; Qiu HX; Qiao C; Sun HM; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):859-62. PubMed ID: 20723288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
    Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
    Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
    Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
    Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
    Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
    Ahmad F; Rajput S; Mandava S; Das BR
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
    Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
    Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
    Preudhomme C; Sagot C; Boissel N; Cayuela JM; Tigaud I; de Botton S; Thomas X; Raffoux E; Lamandin C; Castaigne S; Fenaux P; Dombret H;
    Blood; 2002 Oct; 100(8):2717-23. PubMed ID: 12351377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and therapeutic efficacy of normal karyotype AML patients with CEBPA mutation].
    Du YZ; Su L; Li W; Yu P; Tan YH; Lin H; Gao SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):16-9. PubMed ID: 24598643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
    Benthaus T; Schneider F; Mellert G; Zellmeier E; Schneider S; Kakadia PM; Hiddemann W; Bohlander SK; Feuring-Buske M; Braess J; Spiekermann K; Dufour A
    Br J Haematol; 2008 Oct; 143(2):230-9. PubMed ID: 18752591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
    Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
    Lin LI; Chen CY; Lin DT; Tsay W; Tang JL; Yeh YC; Shen HL; Su FH; Yao M; Huang SY; Tien HF
    Clin Cancer Res; 2005 Feb; 11(4):1372-9. PubMed ID: 15746035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.
    Kim S; Kim DH; Jang JH; Jung CW; Jang MA; Ki CS; Kim JW; Kim SH; Kim HJ
    Ann Lab Med; 2012 Mar; 32(2):153-7. PubMed ID: 22389883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.